Gene Expression Profiling Predicts Olaparib Response in Malignant Pleural Mesothelioma

Study Background and Research Question

Malignant pleural mesothelioma (MPM) is a highly aggressive cancer originating from the pleura and is often associated with poor prognosis, with median survival rates rarely exceeding 12 months despite advances in therapy. The current standard of care for unresectable or advanced MPM combines cisplatin and pemetrexed disodium, but therapeutic response rates remain suboptimal, often not exceeding 40% according to the reference study. One of the major contributors to therapy resistance is believed to be the tumor cells' ability to repair DNA damage through robust DNA repair pathways. The study by Borchert et al. (2019) addresses whether defects in the homologous recombination repair (HRR) pathway—collectively termed "BRCAness"—can serve as biomarkers for predicting the efficacy of PARP inhibitor therapies, such as olaparib, in MPM.

Key Innovation from the Reference Study

The central innovation of Borchert et al. lies in the integration of gene expression profiling with functional drug sensitivity assays to unravel the relationship between HRR pathway integrity and susceptibility to PARP inhibition in MPM. By extending the concept of BRCAness beyond classical BRCA1/2 mutations to include additional HRR gene alterations (notably BAP1), the study provides a molecular framework for stratifying patients who may benefit from olaparib-based therapies. This approach moves the field toward precision oncology by linking mechanistic DNA repair vulnerabilities with targeted treatment options.

Methods and Experimental Design Insights

Borchert et al. employed a multi-tiered experimental strategy. Three distinct MPM cell lines, characterized by varying HRR gene statuses, were used alongside normal lung fibroblasts as controls. The cell lines were exposed to pemetrexed, cisplatin, and olaparib, both as single agents and in combinations. To investigate the molecular determinants of drug response, the authors profiled the expression of HRR pathway genes (including BAP1, AURKA, RAD50, and DDB2) in both cell lines and a clinical cohort of 91 MPM patient samples. Key endpoints included apoptosis induction, senescence markers, and cell viability following treatment. Importantly, the study evaluated the correlation between specific gene expression patterns—indicative of BRCAness—and sensitivity to PARP inhibition.

Protocol Parameters

• Drug exposure duration: 72-hour treatment cycles for pemetrexed, cisplatin, and olaparib in vitro, reflecting typical timescales for assessing apoptosis and senescence.
• Cell line selection: Inclusion of BAP1-mutated and wild-type MPM lines to model the spectrum of HRR competence.
• Gene expression profiling: Digital screening of 91 clinical MPM samples for HRR pathway member expression, enabling stratification based on BRCAness signatures.
• Combination therapy assays: Co-administration of olaparib with cisplatin to assess potential synergistic effects, particularly in BRCAness-positive backgrounds.

Core Findings and Why They Matter

The study demonstrates that MPM cell lines harboring BAP1 mutations—a key marker of the BRCAness phenotype—exhibit heightened sensitivity to the PARP inhibitor olaparib, particularly when combined with cisplatin. Apoptosis and cellular senescence were significantly elevated in these lines following treatment, supporting the hypothesis that HRR defects sensitize cells to PARP inhibition. Furthermore, the gene expression patterns defining BRCAness were identified in approximately 10% of the patient samples, suggesting that a meaningful subset of MPM patients could benefit from HRR-targeted therapies. Prognostic markers such as AURKA, RAD50, and DDB2 expression levels also correlated with survival outcomes, underscoring the translational potential of these molecular signatures. Collectively, these results offer a rationale for incorporating HRR profiling into clinical decision-making for MPM and support the expansion of PARP inhibitor use beyond BRCA1/2-mutant contexts.

Comparison with Existing Internal Articles

The findings of Borchert et al. intersect with established research on the role of antifolate antimetabolites like pemetrexed in cancer chemotherapy research. For instance, internal resources such as "Pemetrexed as a Systems Biology Tool: Dissecting DNA Repair Pathways" and "Pemetrexed as a Precision Tool for Dissecting Folate Metabolism and DNA Repair" highlight the compound’s utility in probing nucleotide biosynthesis and DNA repair vulnerabilities. Pemetrexed’s established function as a TS, DHFR, and GARFT inhibitor makes it highly relevant for modeling chemoresistance and DNA repair dependencies in tumor cell lines, paralleling the mechanistic focus of the reference study. Notably, these articles emphasize the importance of integrating antifolate agents in workflows that interrogate DNA repair phenotypes and chemotherapeutic response, which aligns with the approach used by Borchert et al. to combine pemetrexed and DNA repair-targeted agents in MPM models.

Limitations and Transferability

While Borchert et al. provide valuable molecular insights, several limitations temper the immediate generalizability of their results. The in vitro findings, though robust, may not fully recapitulate the complexity of in vivo tumor microenvironments or account for inter-patient heterogeneity beyond the sampled cohort. The reliance on gene expression profiling, while powerful, requires further validation in prospective clinical trials to establish predictive thresholds for BRCAness and therapy response. Moreover, the proportion of patients exhibiting actionable BRCAness signatures (~10%) underscores the need for broader molecular screening to optimize patient selection. Finally, the study’s combination therapy findings, although promising, warrant additional investigation into toxicity, dosing, and long-term outcomes in diverse clinical settings.

Research Support Resources

For researchers seeking to replicate or extend these findings, high-quality reagents and workflow optimization are critical. Pemetrexed (SKU A4390) is available from APExBIO and can be used as a multi-targeted antifolate for in vitro and in vivo studies of chemoresistance, DNA repair, and antiproliferative mechanisms in tumor cell lines. Its solubility and potency parameters support a range of experimental assays, complementing protocols that require precise modulation of folate-dependent metabolic pathways. Incorporating pemetrexed into experimental designs allows for systematic interrogation of DNA repair vulnerabilities, as exemplified by the reference study and supported by workflow guidance in internal resources. As always, careful titration and validation in disease-relevant models are essential for translating molecular findings into actionable research advances.